PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Stopped early · Phase 2

Conditions studied: Solid Tumor, Unresectable or Metastatic Melanoma

In brief

To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)

Key facts

Study ID

NCT03993379

Run by

CytomX Therapeutics

People needed

3

Starts

2019-11-20

Expected to finish

2020-05-21

Last updated by the study team

2025-12-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years of age
• Measurable disease as defined by RECIST v1.1
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
• Agree to provide tumor tissue and blood samples for biomarker assessment

You may not qualify if…

• Treatment with cytotoxic chemotherapy, biologic agents, radiation, immunotherapy, or any investigational agent within 28 days prior to the first dose of study treatment.
• Prior therapy with a chimeric antigen receptor T cell-containing regimen
• History of active autoimmune disease(s) including but not limited to inflammatory bowel diseases, rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis, systemic sclerosis, systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathies, type 1 insulin-dependent diabetes mellitus
• History of myocarditis regardless of the cause
• History of intolerance to prior checkpoint inhibitor therapy defined as the need to discontinue treatment due to an irAE
• History of any syndrome or medical condition that required treatment with systemic steroids (≥10 mg daily prednisone equivalents) or immunosuppressive medications.
• History of severe allergic or anaphylactic reactions to human mAb therapy or known hypersensitivity to any Probody therapeutic

Where it is running

• City of Hope National Medical Center — Duarte, California, United States
• The Angeles Clinic and Research Institute — Los Angeles, California, United States
• Beacon Cancer Care — Coeur d'Alene, Idaho, United States
• University of Chicago — Chicago, Illinois, United States
• Norton Cancer Institute — Louisville, Kentucky, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• NYC Cancer Institute — New York, New York, United States
• Columbia Medical Center — New York, New York, United States
• Oregon Health & Science Center — Portland, Oregon, United States
• Providence Portland Medical Center — Portland, Oregon, United States
• UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania, United States
• Inova Dwight and March Schar Cancer Institute — Fairfax, Virginia, United States
• Virginia Cancer Specialists — Fairfax, Virginia, United States
• Multicare Institute for Research and Innovation — Spokane, Washington, United States
• Sunshine Coast University Private Hospital — Sunshine Coast, Queensland, Australia
• Ballarat Oncology and Haematology Services — Wendouree, Victoria, Australia
• The Netherlands Cancer Institute — Amsterdam, Netherlands
• University Medical Center Groningen — Groningen, Netherlands
• Asan Medical Center — Seoul, South Korea
• Samsung Medical Center — Seoul, South Korea
• Seoul National University Hospital — Seoul, South Korea
• Severance Hospital Yonsei University Health System — Seoul, South Korea
• ICO Hospitalet, Hospital Duran I Reynals — Barcelona, Spain
• Hospital Clinic de Barcelona. Servicio Oncologia Medica — Barcelona, Spain
• Hospital Universitario La Paz — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.